Overview

Phase I Trial HIPEC With Nal-irinotecan

Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effectiveness and safety of intraperitoneal administration of heated nanoliposomal Irinotecan in cytoreductive surgery (CRS), which is surgery designed to remove as much of the cancer as possible, and heated intraperitoneal chemotherapy (HIPEC) procedures.
Phase:
Phase 1
Details
Lead Sponsor:
Stony Brook University
Collaborators:
Barbara Ann Karmanos Cancer Institute
Ipsen
University of Iowa
University of Kentucky
University of San Diego
Treatments:
Irinotecan